The present invention provides a heart tissue model of at least 60% cardiac cells, wherein the cardiac cells surround an inner cavity, wherein the cardiac cells are selected from cardiomyocytes, endocardial cells and epicardial cells; method for the generation of such a tissue model and uses thereof.

Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects.

Methods for culturing cells, compositions comprising the cell culture product, and applications for the compositions are described. Methods include culturing cells with a media that includes a catalyst compound, which can include a stilbene or a nicotinamide compound, so as to control the secretome of the cells. Compositions that include the cell culture product include the cell secretome or components thereof in conjunction with at least one catalyst compound. Products can be utilized as a cell culture media or can be utilized in therapeutic applications.

A synthetic tissue-graft scaffold (10) includes one or more nominally identical scaffold cages (12) that are configured to facilitate regrowth of tissue of an organism in and around the scaffold cages. Each scaffold cage comprises a volumetric enclosure (14) bounded by a perforated wall structure (30) that has an interior surface (32) and an exterior surface (34). A first annular inlet (22) and second annular inlet (24) positioned at opposite ends of the enclosure form, respectively, a first conjoining surface (54) and a second conjoining surface (56) that are configured so that confronting conjoining surfaces form complementary surfaces to each other. A perforated platform (60) is bounded by the interior surface of the enclosure and provides passageways (62) within the interior chamber. Corridors (40) extend through the perforated wall structure and communicate with the passageways to enable migration of material within and out of the cage.

The invention relates to the technical filed of tissue engineering and 3D printing, particularly relates to an artificial tissue progenitor and a method for preparing the same. In particular, the invention relates to an artificial tissue progenitor comprising a solid support and a plurality of microcapsules, wherein at least one microcapsule is attached to the solid support, and the microcapsule comprises a cell and a biocompatible material encapsulating the cell, to a method for preparing the artificial tissue progenitor, to a kit and a package useful for preparing the artificial tissue progenitor, to an artificial tissue obtained by culturing the artificial tissue progenitor, such as an artificial lumen, to a lumen implant or a lumen model containing the artificial tissue progenitor or the artificial lumen, to use of the artificial tissue progenitor in the manufacture of an artificial tissue, a lumen implant or a lumen model, and to use of the artificial tissue in the manufacture of a lumen implant or lumen model.

Embodiments of the disclosure provide a dissolvable or degradable artificial circulation system for engineering, culturing, and integrating large volume tissues. Also provided are methods of using large engineered tissues prepared using the degradable artificial circulation system for clinical applications and for various applications such as large-scale production of therapeutic or consumable products, drug discovery, and toxicity screening.

The disclosure relates to a melt electrowritten soft tissue scaffold and methods of making the same. The scaffold has a body having a first region comprising a first set of fibres and a second set of fibres, the first region being anisotropic. The first set of fibres are arranged approximately parallel relative to one another, each fibre of the first set of fibres has a serpentine arrangement forming peaks and troughs, the first set of fibres has a first Young's modulus. The second set of fibres are arranged approximately parallel relative to one another, the second set of fibres being arranged transversely relative to the first set of fibres, each fibre of the second set of fibres has a serpentine arrangement forming peaks and troughs, the second set of fibres has a second Young's modulus. The first Young's modulus is unequal to the second Young's modulus. In some embodiments the body further comprises a second region extending from the first region. The second region supports the first region.

A method for characterising a tissue-engineered construct and the tissue-engineered construct are described. The characterisation method allows verification of viability, morphology, functionality and/or distribution of cells comprised in the tissue-engineered construct. The tissue-engineered construct has a scaffold with a lumen and at least one portion of the lumen lined with at least one functional and preferably continuous cell layer, that can be used for in vitro testing of medicinal products for human or animal use. A method for the in vitro testing of medicinal products for human or animal use performed with the tissue-engineered construct is also described.

Provided herein are methods and systems for bio-printing of three-dimensional organs and organoids. Also provided herein are bio-printed three-dimensional organs and organoids for use in the generation and/or the assessment of immunological products and/or immune responses. Also provided herein are methods and system for bio-printing three-dimensional matrices.

The present disclosure provides, in some embodiments, in vitro blood brain barrier (iBBB) having functional properties of in vivo BBB as well as methods of identifying compounds capable of traversing the iBBB. Compounds capable of crossing the iBBB and therapeutic uses of such compounds are also described.